A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference Drug

NCT01888445 PHASE2 COMPLETED

This study is to evaluate safety and efficacy of intermittent oral dosing of ASP1517 in dialysis chronic kidney disease patients with anemia.

Details

Lead sponsor	Astellas Pharma Inc
Phase	PHASE2
Status	COMPLETED
Enrolment	130
Start date	Thu Mar 28 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Sep 15 2014 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Renal Anemia Associated With Chronic Renal Failure (CRF)

Interventions

• roxadustat
• darbepoetin alfa

Countries

Japan